Drug Profile
Mifepristone - VGX Pharmaceuticals
Alternative Names: PICTOVIR; VGX-410; VGX-410CLatest Information Update: 11 Dec 2021
Price :
$50
*
At a glance
- Originator VGX Pharmaceuticals
- Class Abortifacients; Antidementias; Antidepressants; Antiglaucomas; Antineoplastics; Antiprogestogens; Antipsychotics; Antivirals; Dimethylamines; Estrenes; Eye disorder therapies; Obesity therapies; Oral contraceptives; Small molecules; Smoking cessation therapies
- Mechanism of Action Glucocorticoid receptor antagonists; Hepatitis C internal ribosome entry site inhibitors; HIV pre-integration complex translocation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C; HIV infections
Most Recent Events
- 02 Sep 2007 VGX Pharmaceuticals completes enrolment in the VT003 trial for Hepatitis C virus infections in the US
- 21 Feb 2007 VGX 410 licensed to VGX International to sell and market in Asia and other developing regions, including Africa
- 17 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the adverse events and Viral Infections therapeutic trials sections